Understand the mode of action
of your compound

The ultimate understanding of the Mode of Action (MoA) of your compound resides in taking a patient-centric approach. This means finding what the differences are at the molecular level between individuals on the same treatment.

Therefore, at the inception of any drug discovery and development program, it isn’t enough just to focus on the pathology. The program must also focus on the ‘clinical reality’ in which the patient is being treated. Inoviem enables you to achieve this clinical reality by bringing patients to the bench; their own tissue is included in the study and the results used as ‘reference’. We are able to identify everything from the extracellular and the nucleus to as far as the organs, enabling you to make better informed decisions on how to pursue your drug development program.

Related case studies

Validate targets in the study model

Compound pharmacology is always shown in a relevant model, whether cellular or animal. It is important to identify and validate the primary target in the very same model.

Therefore, we identify target candidates (n=5) that are validated in the study model; these could be cell line, primary cells, iPS, or any animal model.

Insufficient validation of drug targets at an early stage has been linked to costly clinical failures. Inoviem is adept at overcoming the key challenges in target validation that could otherwise impact not only the model, but beyond that, in the patient:

  • The compound interacts directly with the identified target
  • The identified target is delivered in the pathology. As it plays a key role, once modified, it would have an effect on the disease
  • The interaction between the compound and target can change the pharmacology of the target within the disease area

Choose your lead compound

With greater emphasis on translational pharmacology, any number of compounds can be profiled, and we can identify within four weeks of study which one of these offers the best ‘druggability’ to move forward into development.

This fast turnaround will help you significantly reduce the time and cost in qualifying a compound from ‘hit’ to ‘lead’. Once the target has been validated for the lead compound, you can then return to the initial batch of compounds, rank them based on the identified target and keep them as back-up.

Related case studies

Stratify different patient groups

The lack of efficacy in Phase II clinical trials is a major factor in the overall failure rate of drug candidates. A contributing factor is insufficient investigational study due to patient heterogeneity.

Inoviem harnesses its study power to locate and identify within the whole population the right patient subset (Read more information) who would respond to the compound. This is a non-Gaussian distribution approach: identifying the hotspot within the population who would respond. By working on this select population, Inoviem can provide assurances that your investigational agent will achieve the required pharmacology compared to the placebo.

Identify secondary targets

If you suspect that a secondary target may be problematic, we can quickly identify whether it is beneficial to the indication or produces side-effects.

As this can be determined at the pre-clinical phase or during clinical phases 1 to 3, our translational pharmacology approach enables you to reduce attrition rates in phase II clinical trials by discovering negative side-effects way ahead of your drug entering phase IV or being introduced on the market.

Validate target in targeted organism

Our robust empirical approach enables you to salvage a failed compound by finding a new indication for it. We enable you to quickly reposition a compound.

Define the indication

When your promising compound has failed in its primary indication, through our empirical approach, we can fast-track you to identifying a condition that would be more efficient, realizing the full potential of your compound’s pharmacological function.

Related case studies

Identify success biomarkers

Inoviem works with drug developers to overcome the key challenges in showing the efficacy of a compound: the complexity of the disease, the individual differences within the disease area, lack of knowledge of the pathophysiology.

Inoviem’s translational pharmacology strategy goes beyond genomic approaches, to give  you more information than just the genetic function of a disease.

  • Identify unexpected natural protein interactions

It is vital that you are aware of any unanticipated interactions. Our technologies are able to isolate the whole interactome of your therapeutic target, identify unexpected natural protein interactions and ultimately identify the biomarker.

  • Molecular differences in sub-groups

If you are looking to find out more about different sub-groups (responders and non-responders), we can use our PIMS label-free technology to analyze their molecular differences and identify biomarkers.

  • Reliability testing

We also develop innovative tests associated with an identified biomarker so that you can benefit from a reliable test which is validated with clinicians.